LENZ Therapeutics, Inc. Insider Trading

LENZ

⊜ Compare

Last 12 months

Insiders bought 655K and sold 261K on the open market.

All of the selling was scheduled in advance under 10b5-1 plans.

Net open-market

+394K

5 buys · 1 sale

Under a 10b5-1 plan

100%

of the value sold

Insiders who bought / sold

4 / 1

executives and directors

Last open-market buy

Mar 2026

Mar 27, 2026

Get an email when LENZ's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Oct 29	RA Capital Management, L.p. Large holder	SoldNo plan 3 parts	2,718,684	$3.36 average	$9.13M	98%	Form 4
Mar 27	Jeffrey P. George Director	Bought	5,592	$8.92	50K	New	Form 4
Mar 27	Evert B. Schimmelpennink President, CEO and Secretary	Bought	28,089	$8.95	251K	57%	Form 4
Mar 27	Daniel R. Chevallard Chief Financial Officer	Bought	7,500	$8.57	64K	139%	Form 4
Nov 17, 2025	Shawn Olsson Chief Commercial Officer	Sold10b5-1 plan 2 parts	10,000	$26.10 average	261K	68%	Form 4
Nov 7, 2025	James W McCollum Director	Bought	10,500	$22.79	239K	1.7%	Form 4
Nov 7, 2025	Daniel R. Chevallard Chief Financial Officer	Bought 2 parts	2,198	$22.76 average	50K	69%	Form 4
Sep 30, 2025	Versant Vantage II Gp-Gp, LLC Large holder	SoldNo plan 6 parts	224,974	$46.01 average	$10.4M	7.9%	Form 4
Sep 18, 2025	Versant Venture Capital VI, L.p. Large holder	SoldNo plan 6 parts	135,304	$42.23 average	$5.71M	4.4%	Form 4
Aug 22, 2025 – Aug 26, 2025	Versant Ventures VII GP, L.p. Large holder	SoldNo plan 12 parts	188,094	$39.47 average	$7.42M	5.7%	Form 4
Aug 15, 2025 – Aug 18, 2025	Versant Venture Capital VI, L.p. Large holder	SoldNo plan 4 parts	260,713	$39.34 average	$10.3M	7.2%	Form 4
Jul 10, 2025	Versant Ventures VII Gp-Gp, LLC Large holder	SoldNo plan	191,376	$34.00	$6.51M	7.3%	Form 4
Jun 27, 2025	Versant Vantage II Gp-Gp, LLC Large holder	SoldNo plan	200,000	$30.47	$6.09M	7.1%	Form 4
Jun 18, 2025 – Jun 20, 2025	Versant Ventures VI GP, L.p. Large holder	SoldNo plan 3 parts	334,801	$30.19 average	$10.1M	10.0%	Form 4
Jun 10, 2025	Versant Vantage II Gp-Gp, LLC Large holder	SoldNo plan	350,000	$29.00	$10.2M	7.7%	Form 4

Oct 29No plan
RA Capital Management, L.p.
Large holder · sold 2,718,684 at avg $3.36
$9.13M
98% of stake
Mar 27
Jeffrey P. George
Director · bought 5,592 at $8.92
50K
New position
Mar 27
Evert B. Schimmelpennink
President, CEO and Secretary · bought 28,089 at $8.95
251K
57% of stake
Mar 27
Daniel R. Chevallard
Chief Financial Officer · bought 7,500 at $8.57
64K
139% of stake
Nov 17, 202510b5-1 plan
Shawn Olsson
Chief Commercial Officer · sold 10,000 at avg $26.10
261K
68% of stake
Nov 7, 2025
James W McCollum
Director · bought 10,500 at $22.79
239K
1.7% of stake
Nov 7, 2025
Daniel R. Chevallard
Chief Financial Officer · bought 2,198 at avg $22.76
50K
69% of stake
Sep 30, 2025No plan
Versant Vantage II Gp-Gp, LLC
Large holder · sold 224,974 at avg $46.01
$10.4M
7.9% of stake
Sep 18, 2025No plan
Versant Venture Capital VI, L.p.
Large holder · sold 135,304 at avg $42.23
$5.71M
4.4% of stake
Aug 22, 2025 – Aug 26, 2025No plan
Versant Ventures VII GP, L.p.
Large holder · sold 188,094 at avg $39.47
$7.42M
5.7% of stake
Aug 15, 2025 – Aug 18, 2025No plan
Versant Venture Capital VI, L.p.
Large holder · sold 260,713 at avg $39.34
$10.3M
7.2% of stake
Jul 10, 2025No plan
Versant Ventures VII Gp-Gp, LLC
Large holder · sold 191,376 at $34.00
$6.51M
7.3% of stake
Jun 27, 2025No plan
Versant Vantage II Gp-Gp, LLC
Large holder · sold 200,000 at $30.47
$6.09M
7.1% of stake
Jun 18, 2025 – Jun 20, 2025No plan
Versant Ventures VI GP, L.p.
Large holder · sold 334,801 at avg $30.19
$10.1M
10.0% of stake
Jun 10, 2025No plan
Versant Vantage II Gp-Gp, LLC
Large holder · sold 350,000 at $29.00
$10.2M
7.7% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch LENZ, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Biological Products, (No Diagnostic Substances) · Pick stocks to compare with LENZ

CompareIntrinsic value

ELUTElutia Inc.

$0.76-6.52%20

LCTXLineage Cell Therapeutics Inc.

$1.03+1.98%10

RVMDRevolution Medicines Inc.

$199.21+2.56%10

SRZNSurrozen, Inc.

$31.65+5.08%10

ALECAlector Inc.

$2.28+11.22%10

RLAYRelay Therapeutics Inc.

$18.03+3.38%40

CRBUCaribou Biosciences, Inc.

$0.44-3.27%10

ACOGAlpha Cognition Inc.

$8.49+3.48%10

Held by ETFs

LENZ is in 7 US ETFs. The largest of them, with LENZ's weight in each:

Spot a number that looks wrong? Check it in LENZ's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing LENZ

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.